Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mesothelioma 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 12Nivolumab 4tislelizumab 2spartalizumab 2belinostat 2atezolizumab 2Ipilimumab 2venetoclax 1tocilizumab 1talazoparib 1rovalpituzumab tesirine 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1durvalumab 1budigalimab 1Tablets 1Sorafenib 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1LY2940680 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Doxepin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × milademetan × Head & Neck × Clear all
NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡